Theravance Biopharma Said On Dec 26 Units, Mylan Ireland & Mylan Specialty Entered Settlement Agreement With Accord Healthcare Relating To Yupelri (Revefenacin) Inhalation Solution
Portfolio Pulse from Charles Gross
Theravance Biopharma, through its units Mylan Ireland and Mylan Specialty, has entered into a settlement agreement with Accord Healthcare concerning Yupelri (Revefenacin) Inhalation Solution. As part of the agreement, Accord Healthcare has been granted a license to manufacture and market a generic version of Yupelri in the U.S. starting after April 23, 2039.
December 28, 2023 | 11:21 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Theravance Biopharma's settlement with Accord Healthcare grants a license for a generic version of Yupelri, but not until after April 2039.
The settlement agreement secures Theravance Biopharma's market exclusivity for Yupelri until 2039, which is positive as it delays generic competition. However, the impact is long-term and the immediate financial implications are likely minimal, hence the importance is not at the maximum. The confidence in this analysis is high due to the clear terms of the agreement.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100